Advertisement

Topics

Syngenix Limited Company Profile

07:21 EDT 22nd June 2018 | BioPortfolio

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery probes such as antisense in vivo for > drug target validation and systems for targeting small drugs and macromolecules to the site of disease. The core platform technologies have been demonstrated by the intracellular delivery of drugs to treat chronic pain and the delivery of antisense to block HIV. SynGenix now intends to take technology to treat chronic and acute pain into man over the coming 24 months and to develop related technologies to target therapeutic and probe molecules to address other unmet disease needs.

Location

Babraham Hall Babraham
Cambridge
Cambridgeshire
CB2 4AT
United Kingdom

Contact

Phone: +44 1223 496090
Fax: +44 1223 496018


News Articles [29 Associated News Articles listed on BioPortfolio]

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July ...

Genetic Technologies Limited: Update on Strategic Alliance

MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”), wishes to advise that the Company is presently in discussi...

Genetic Technologies Limited: Project Shivom Strategic Alliance

MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG)  (NASDAQ:GENE) (“Company”, “GTG”) a diversified molecular diagnostics company; provider of...

Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

JERSEY, Channel Islands, May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validatio...

Quotient Limited appoints Franz Walt as Chief Executive Officer

JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executi...

Quotient Limited Announces Appointment of Franz Walt as Non-Executive Director

JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt to its board of...

Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) announced today that it has received a milestone payment from the Company’s Chinese partner for efti...

Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

Field trial concordance data exceed targeted criteriaPlanned issuance of $36 million in Senior Secured Notes JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QT...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [83 Associated Companies listed on BioPortfolio]

Syngenix Limited

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery ...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

VASUDHA PHARMA CHEM LIMITED

VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...

More Information about "Syngenix Limited" on BioPortfolio

We have published hundreds of Syngenix Limited news stories on BioPortfolio along with dozens of Syngenix Limited Clinical Trials and PubMed Articles about Syngenix Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Syngenix Limited Companies in our database. You can also find out about relevant Syngenix Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...


Corporate Database Quicklinks



Searches Linking to this Company Record